rabbit polyclonal anti akt Search Results


anti akt  (Cusabio)
93
Cusabio anti akt
Anti Akt, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+akt/pm29577269-127-29-31?v=Cusabio
Average 93 stars, based on 1 article reviews
anti akt - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
akt  (Cusabio)
91
Cusabio akt
Figure 2. Characterization of 3,2′-DHF-treated WJ-MSCs and EVs. (A) The proliferation rate of WJ- MSC treated with various concentrations of 3,2′-DHF. WJ-MSCs have the best proliferation rate with 1–2 µM 3,2′-DHF. Statistical analysis was determined using one-way ANOVA with Tukey’s multiple comparisons test: ** p < 0.05, **** p < 0.0001. (B) Protein expression of MEK/ERK signaling proteins in WJ-MSCs with and without 3,2′-DHF treatment. The bar graph shows the protein expression of <t>AKT</t> and MEK in 3,2′-DHF-treated and untreated WJ-MSCs. (C) Flow cytometry analysis to confirm the characteristics of WJ-MSCs with or without 3,2′-DHF. The expression of the positive markers CD73, CD90, and CD105, and the negative markers CD34 and CD45, was assessed. (D) The relative EV production amounts of Cont-EV and Fla-EV were measured using nanoparticle tracking analysis (NTA). Statistical analysis was determined using two-way ANOVA: **** p < 0.0001. (E) Transmission electron microscopy (TEM) images of Cont-EV and Fla-EV. Scale bar: 100 nm. The size of the EVs was determined with NTA. (F) Characterization of EV-positive markers CD9 and CD63, and negative markers calnexin <t>and</t> <t>GM130,</t> in Cont-EV and Fla-EV using Western blotting. (G) Representative plot of EV-surface markers CD63 and CD81 in Cont-EV and Fla-EV via flow cytometry analysis.
Akt, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+akt/pm37108128-243-37-39?v=Cusabio
Average 91 stars, based on 1 article reviews
akt - by Bioz Stars, 2026-07
91/100 stars
  Buy from Supplier
csb pa008120  (Cusabio)
91
Cusabio csb pa008120
Figure 2. Characterization of 3,2′-DHF-treated WJ-MSCs and EVs. (A) The proliferation rate of WJ- MSC treated with various concentrations of 3,2′-DHF. WJ-MSCs have the best proliferation rate with 1–2 µM 3,2′-DHF. Statistical analysis was determined using one-way ANOVA with Tukey’s multiple comparisons test: ** p < 0.05, **** p < 0.0001. (B) Protein expression of MEK/ERK signaling proteins in WJ-MSCs with and without 3,2′-DHF treatment. The bar graph shows the protein expression of <t>AKT</t> and MEK in 3,2′-DHF-treated and untreated WJ-MSCs. (C) Flow cytometry analysis to confirm the characteristics of WJ-MSCs with or without 3,2′-DHF. The expression of the positive markers CD73, CD90, and CD105, and the negative markers CD34 and CD45, was assessed. (D) The relative EV production amounts of Cont-EV and Fla-EV were measured using nanoparticle tracking analysis (NTA). Statistical analysis was determined using two-way ANOVA: **** p < 0.0001. (E) Transmission electron microscopy (TEM) images of Cont-EV and Fla-EV. Scale bar: 100 nm. The size of the EVs was determined with NTA. (F) Characterization of EV-positive markers CD9 and CD63, and negative markers calnexin <t>and</t> <t>GM130,</t> in Cont-EV and Fla-EV using Western blotting. (G) Representative plot of EV-surface markers CD63 and CD81 in Cont-EV and Fla-EV via flow cytometry analysis.
Csb Pa008120, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+akt/pmc11331723-34-8-6?v=Cusabio
Average 91 stars, based on 1 article reviews
csb pa008120 - by Bioz Stars, 2026-07
91/100 stars
  Buy from Supplier
p akt s473  (Cusabio)
90
Cusabio p akt s473
Figure 2. Characterization of 3,2′-DHF-treated WJ-MSCs and EVs. (A) The proliferation rate of WJ- MSC treated with various concentrations of 3,2′-DHF. WJ-MSCs have the best proliferation rate with 1–2 µM 3,2′-DHF. Statistical analysis was determined using one-way ANOVA with Tukey’s multiple comparisons test: ** p < 0.05, **** p < 0.0001. (B) Protein expression of MEK/ERK signaling proteins in WJ-MSCs with and without 3,2′-DHF treatment. The bar graph shows the protein expression of <t>AKT</t> and MEK in 3,2′-DHF-treated and untreated WJ-MSCs. (C) Flow cytometry analysis to confirm the characteristics of WJ-MSCs with or without 3,2′-DHF. The expression of the positive markers CD73, CD90, and CD105, and the negative markers CD34 and CD45, was assessed. (D) The relative EV production amounts of Cont-EV and Fla-EV were measured using nanoparticle tracking analysis (NTA). Statistical analysis was determined using two-way ANOVA: **** p < 0.0001. (E) Transmission electron microscopy (TEM) images of Cont-EV and Fla-EV. Scale bar: 100 nm. The size of the EVs was determined with NTA. (F) Characterization of EV-positive markers CD9 and CD63, and negative markers calnexin <t>and</t> <t>GM130,</t> in Cont-EV and Fla-EV using Western blotting. (G) Representative plot of EV-surface markers CD63 and CD81 in Cont-EV and Fla-EV via flow cytometry analysis.
P Akt S473, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+akt/pmc08316451-220-63-67?v=Cusabio
Average 90 stars, based on 1 article reviews
p akt s473 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
akt1 akt2 akt3  (Cusabio)
90
Cusabio akt1 akt2 akt3
Figure 2. Characterization of 3,2′-DHF-treated WJ-MSCs and EVs. (A) The proliferation rate of WJ- MSC treated with various concentrations of 3,2′-DHF. WJ-MSCs have the best proliferation rate with 1–2 µM 3,2′-DHF. Statistical analysis was determined using one-way ANOVA with Tukey’s multiple comparisons test: ** p < 0.05, **** p < 0.0001. (B) Protein expression of MEK/ERK signaling proteins in WJ-MSCs with and without 3,2′-DHF treatment. The bar graph shows the protein expression of <t>AKT</t> and MEK in 3,2′-DHF-treated and untreated WJ-MSCs. (C) Flow cytometry analysis to confirm the characteristics of WJ-MSCs with or without 3,2′-DHF. The expression of the positive markers CD73, CD90, and CD105, and the negative markers CD34 and CD45, was assessed. (D) The relative EV production amounts of Cont-EV and Fla-EV were measured using nanoparticle tracking analysis (NTA). Statistical analysis was determined using two-way ANOVA: **** p < 0.0001. (E) Transmission electron microscopy (TEM) images of Cont-EV and Fla-EV. Scale bar: 100 nm. The size of the EVs was determined with NTA. (F) Characterization of EV-positive markers CD9 and CD63, and negative markers calnexin <t>and</t> <t>GM130,</t> in Cont-EV and Fla-EV using Western blotting. (G) Representative plot of EV-surface markers CD63 and CD81 in Cont-EV and Fla-EV via flow cytometry analysis.
Akt1 Akt2 Akt3, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+akt/pmc06882982-292-29-30?v=Cusabio
Average 90 stars, based on 1 article reviews
akt1 akt2 akt3 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
anti-p-akt(ser473)  (GeneTex)
90
GeneTex anti-p-akt(ser473)
Figure 2. Characterization of 3,2′-DHF-treated WJ-MSCs and EVs. (A) The proliferation rate of WJ- MSC treated with various concentrations of 3,2′-DHF. WJ-MSCs have the best proliferation rate with 1–2 µM 3,2′-DHF. Statistical analysis was determined using one-way ANOVA with Tukey’s multiple comparisons test: ** p < 0.05, **** p < 0.0001. (B) Protein expression of MEK/ERK signaling proteins in WJ-MSCs with and without 3,2′-DHF treatment. The bar graph shows the protein expression of <t>AKT</t> and MEK in 3,2′-DHF-treated and untreated WJ-MSCs. (C) Flow cytometry analysis to confirm the characteristics of WJ-MSCs with or without 3,2′-DHF. The expression of the positive markers CD73, CD90, and CD105, and the negative markers CD34 and CD45, was assessed. (D) The relative EV production amounts of Cont-EV and Fla-EV were measured using nanoparticle tracking analysis (NTA). Statistical analysis was determined using two-way ANOVA: **** p < 0.0001. (E) Transmission electron microscopy (TEM) images of Cont-EV and Fla-EV. Scale bar: 100 nm. The size of the EVs was determined with NTA. (F) Characterization of EV-positive markers CD9 and CD63, and negative markers calnexin <t>and</t> <t>GM130,</t> in Cont-EV and Fla-EV using Western blotting. (G) Representative plot of EV-surface markers CD63 and CD81 in Cont-EV and Fla-EV via flow cytometry analysis.
Anti P Akt(ser473), supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+akt/pmc03150327-55-0-10?v=GeneTex
Average 90 stars, based on 1 article reviews
anti-p-akt(ser473) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
anti-akt rabbit polyclonal igg  (Biomol GmbH)
90
Biomol GmbH anti-akt rabbit polyclonal igg
Figure 2. Characterization of 3,2′-DHF-treated WJ-MSCs and EVs. (A) The proliferation rate of WJ- MSC treated with various concentrations of 3,2′-DHF. WJ-MSCs have the best proliferation rate with 1–2 µM 3,2′-DHF. Statistical analysis was determined using one-way ANOVA with Tukey’s multiple comparisons test: ** p < 0.05, **** p < 0.0001. (B) Protein expression of MEK/ERK signaling proteins in WJ-MSCs with and without 3,2′-DHF treatment. The bar graph shows the protein expression of <t>AKT</t> and MEK in 3,2′-DHF-treated and untreated WJ-MSCs. (C) Flow cytometry analysis to confirm the characteristics of WJ-MSCs with or without 3,2′-DHF. The expression of the positive markers CD73, CD90, and CD105, and the negative markers CD34 and CD45, was assessed. (D) The relative EV production amounts of Cont-EV and Fla-EV were measured using nanoparticle tracking analysis (NTA). Statistical analysis was determined using two-way ANOVA: **** p < 0.0001. (E) Transmission electron microscopy (TEM) images of Cont-EV and Fla-EV. Scale bar: 100 nm. The size of the EVs was determined with NTA. (F) Characterization of EV-positive markers CD9 and CD63, and negative markers calnexin <t>and</t> <t>GM130,</t> in Cont-EV and Fla-EV using Western blotting. (G) Representative plot of EV-surface markers CD63 and CD81 in Cont-EV and Fla-EV via flow cytometry analysis.
Anti Akt Rabbit Polyclonal Igg, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+akt/pmc06670965-82-9-16?v=Biomol+GmbH
Average 90 stars, based on 1 article reviews
anti-akt rabbit polyclonal igg - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
rabbit anti-phospho (p)-akt polyclonal antibody  (MyBiosource Biotechnology)
90
MyBiosource Biotechnology rabbit anti-phospho (p)-akt polyclonal antibody
Relative expression levels of BIRC5 mRNA and protein in different cell lines with or without SC79 treatment. (A) The effect of SC79 treatment on the expression levels of <t>p-AKT</t> in different cell lines. (B) Relative mRNA expression levels of BIRC5 in different cell lines. (C) Representative western blot analysis results of BIRC5. (D) Relative protein expression levels of BIRC5 in different cell lines. (E) The effect of SC79 treatment on the expression levels of VEGF in different cell lines. (F) The effect of SC79 treatment on the expression levels of BAI1 in different cell lines. (G) The effect of BAI1 treatment on the expression levels of MBD2 in different cell lines. *P<0.05 vs. untreated cells. BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; MBD2, methyl-CpG binding domain protein 2; BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; BAI1, brain-specific angiogenesis inhibitor 1; MBD2, methyl-CpG binding domain protein 2; p-Akt, <t>phospho-Akt.</t>
Rabbit Anti Phospho (P) Akt Polyclonal Antibody, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+akt/pmc06096085-75-62-72?v=MyBiosource+Biotechnology
Average 90 stars, based on 1 article reviews
rabbit anti-phospho (p)-akt polyclonal antibody - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
polyclonal rabbit anti-human anti-p akt (ser473) antibody (cat no. bs4006)  (Bioworld Antibodies)
90
Bioworld Antibodies polyclonal rabbit anti-human anti-p akt (ser473) antibody (cat no. bs4006)
Relative expression levels of BIRC5 mRNA and protein in different cell lines with or without SC79 treatment. (A) The effect of SC79 treatment on the expression levels of <t>p-AKT</t> in different cell lines. (B) Relative mRNA expression levels of BIRC5 in different cell lines. (C) Representative western blot analysis results of BIRC5. (D) Relative protein expression levels of BIRC5 in different cell lines. (E) The effect of SC79 treatment on the expression levels of VEGF in different cell lines. (F) The effect of SC79 treatment on the expression levels of BAI1 in different cell lines. (G) The effect of BAI1 treatment on the expression levels of MBD2 in different cell lines. *P<0.05 vs. untreated cells. BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; MBD2, methyl-CpG binding domain protein 2; BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; BAI1, brain-specific angiogenesis inhibitor 1; MBD2, methyl-CpG binding domain protein 2; p-Akt, <t>phospho-Akt.</t>
Polyclonal Rabbit Anti Human Anti P Akt (Ser473) Antibody (Cat No. Bs4006), supplied by Bioworld Antibodies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+akt/pmc04487129-65-18-43?v=Bioworld+Antibodies
Average 90 stars, based on 1 article reviews
polyclonal rabbit anti-human anti-p akt (ser473) antibody (cat no. bs4006) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Figure 2. Characterization of 3,2′-DHF-treated WJ-MSCs and EVs. (A) The proliferation rate of WJ- MSC treated with various concentrations of 3,2′-DHF. WJ-MSCs have the best proliferation rate with 1–2 µM 3,2′-DHF. Statistical analysis was determined using one-way ANOVA with Tukey’s multiple comparisons test: ** p < 0.05, **** p < 0.0001. (B) Protein expression of MEK/ERK signaling proteins in WJ-MSCs with and without 3,2′-DHF treatment. The bar graph shows the protein expression of AKT and MEK in 3,2′-DHF-treated and untreated WJ-MSCs. (C) Flow cytometry analysis to confirm the characteristics of WJ-MSCs with or without 3,2′-DHF. The expression of the positive markers CD73, CD90, and CD105, and the negative markers CD34 and CD45, was assessed. (D) The relative EV production amounts of Cont-EV and Fla-EV were measured using nanoparticle tracking analysis (NTA). Statistical analysis was determined using two-way ANOVA: **** p < 0.0001. (E) Transmission electron microscopy (TEM) images of Cont-EV and Fla-EV. Scale bar: 100 nm. The size of the EVs was determined with NTA. (F) Characterization of EV-positive markers CD9 and CD63, and negative markers calnexin and GM130, in Cont-EV and Fla-EV using Western blotting. (G) Representative plot of EV-surface markers CD63 and CD81 in Cont-EV and Fla-EV via flow cytometry analysis.

Journal: International journal of molecular sciences

Article Title: Improved Wound Healing and Skin Regeneration Ability of 3,2'-Dihydroxyflavone-Treated Mesenchymal Stem Cell-Derived Extracellular Vesicles.

doi: 10.3390/ijms24086964

Figure Lengend Snippet: Figure 2. Characterization of 3,2′-DHF-treated WJ-MSCs and EVs. (A) The proliferation rate of WJ- MSC treated with various concentrations of 3,2′-DHF. WJ-MSCs have the best proliferation rate with 1–2 µM 3,2′-DHF. Statistical analysis was determined using one-way ANOVA with Tukey’s multiple comparisons test: ** p < 0.05, **** p < 0.0001. (B) Protein expression of MEK/ERK signaling proteins in WJ-MSCs with and without 3,2′-DHF treatment. The bar graph shows the protein expression of AKT and MEK in 3,2′-DHF-treated and untreated WJ-MSCs. (C) Flow cytometry analysis to confirm the characteristics of WJ-MSCs with or without 3,2′-DHF. The expression of the positive markers CD73, CD90, and CD105, and the negative markers CD34 and CD45, was assessed. (D) The relative EV production amounts of Cont-EV and Fla-EV were measured using nanoparticle tracking analysis (NTA). Statistical analysis was determined using two-way ANOVA: **** p < 0.0001. (E) Transmission electron microscopy (TEM) images of Cont-EV and Fla-EV. Scale bar: 100 nm. The size of the EVs was determined with NTA. (F) Characterization of EV-positive markers CD9 and CD63, and negative markers calnexin and GM130, in Cont-EV and Fla-EV using Western blotting. (G) Representative plot of EV-surface markers CD63 and CD81 in Cont-EV and Fla-EV via flow cytometry analysis.

Article Snippet: The following antibodies were diluted in 1× blocking buffer (TLP-115.1G, Translab): CD9 (ab263023, Abcam, Cambridge, UK), CD63 (ab109201, Abcam), calnexin (2679, Cell Signaling Technology, Danvers, MA, USA), GM130 (12480, Santa Cruz Biotechnology), p-AKT (sc-293125, Santa Cruz Biotechnology), AKT (CSB-PA000855, Cusabio, Houston, TX, USA), p-ERK (CSB-PA000749, Cusabio), ERK (B7074, Tebu-bio, Le Perray, Ile-de-France, France), β-actin (sc-47778, Santa Cruz Biotechnology), HRP-linked anti-rabbit IgG (7074, Santa Cruz Biotechnology), and HRP-linked anti-mouse IgG (7076, Santa Cruz Biotechnology).

Techniques: Expressing, Flow Cytometry, Transmission Assay, Electron Microscopy, Western Blot, Cytometry

Relative expression levels of BIRC5 mRNA and protein in different cell lines with or without SC79 treatment. (A) The effect of SC79 treatment on the expression levels of p-AKT in different cell lines. (B) Relative mRNA expression levels of BIRC5 in different cell lines. (C) Representative western blot analysis results of BIRC5. (D) Relative protein expression levels of BIRC5 in different cell lines. (E) The effect of SC79 treatment on the expression levels of VEGF in different cell lines. (F) The effect of SC79 treatment on the expression levels of BAI1 in different cell lines. (G) The effect of BAI1 treatment on the expression levels of MBD2 in different cell lines. *P<0.05 vs. untreated cells. BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; MBD2, methyl-CpG binding domain protein 2; BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; BAI1, brain-specific angiogenesis inhibitor 1; MBD2, methyl-CpG binding domain protein 2; p-Akt, phospho-Akt.

Journal: Oncology Letters

Article Title: Downregulation of BIRC5 inhibits the migration and invasion of esophageal cancer cells by interacting with the PI3K/Akt signaling pathway

doi: 10.3892/ol.2018.8986

Figure Lengend Snippet: Relative expression levels of BIRC5 mRNA and protein in different cell lines with or without SC79 treatment. (A) The effect of SC79 treatment on the expression levels of p-AKT in different cell lines. (B) Relative mRNA expression levels of BIRC5 in different cell lines. (C) Representative western blot analysis results of BIRC5. (D) Relative protein expression levels of BIRC5 in different cell lines. (E) The effect of SC79 treatment on the expression levels of VEGF in different cell lines. (F) The effect of SC79 treatment on the expression levels of BAI1 in different cell lines. (G) The effect of BAI1 treatment on the expression levels of MBD2 in different cell lines. *P<0.05 vs. untreated cells. BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; MBD2, methyl-CpG binding domain protein 2; BIRC5, baculoviral IAP repeat containing 5; VEGF, vascular endothelial growth factor; BAI1, brain-specific angiogenesis inhibitor 1; MBD2, methyl-CpG binding domain protein 2; p-Akt, phospho-Akt.

Article Snippet: The membranes were then incubated with corresponding primary antibodies including rabbit anti-BIRC5 polyclonal antibody (dilution, 1:1,000; catalog no. MBS151070; MyBioSource, Inc., San Diego, CA, USA), rabbit anti-VEGF polyclonal antibody (dilution, 1:1,000; catalog no. bs-0279R; Biomathematics and Statistics Scotland, Edinburgh, Scotland), rabbit anti-BAI1 polyclonal antibody (dilution, 1:1,000; catalog no. MBS8242484; MyBioSource, Inc.), rabbit anti-MBD2 polyclonal antibody (dilution, 1:1,000; catalog no. MBS126361; MyBioSource, Inc.), rabbit anti-phospho (p)-Akt polyclonal antibody (dilution, 1:1,000; catalog no. MBS330024; MyBioSource, Inc.) and rabbit anti-GAPDH polyclonal antibody (dilution, 1:1,000; catalog no. MBS9216842; MyBioSource, Inc.) overnight at 4°C.

Techniques: Expressing, Western Blot, Binding Assay